L-tryptophan supplementation
Phase 3Small molecule
L-tryptophan supplementation is one of 14 small molecule programs targeting Post-Operative Delirium. It is currently in Phase 3.
1
Indications
1
Total Trials
0
Active Trials
13
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Post-Operative Delirium
#DrugCompanyPhaseTrials
1Exelon
NovartisApproved
Cymbalta
Alnylam PharmaceuticalsApproved
Haldol
DDePuy Orthopaedics
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Rozerem
TakedaPhase 2
Dayvigo
EisaiPhase 2
Namenda
SStanford University
Approved
Riboflavin
CCornea and Laser Eye Institute
Phase 2
Microcrystalline Cellulose
XXenon Pharmaceuticals Inc.
Phase 2
L-tryptophan supplementation
UUniversity of Colorado, Denver
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- UUniversity of Colorado, Denver